Dr. Elena Vasquez
Senior Biomedical Engineer
Bay Area, CA
I am a dedicated Biomedical Engineer with a leading precision genetics testing laboratory known for advanced DNA sequencing and personalized medicine solutions. Bachelor of Science in Biomedical Engineering from the University of California, Berkeley in 2014, followed by a Ph.D. in Bioengineering from Stanford University in 2019, where my research focused on microfluidic devices for high-throughput genetic analysis. Currently I lead the design, integration, and optimization of automated laboratory systems that process thousands of genetic samples daily with next-generation sequencing platforms, robotic liquid handling systems, high-precision thermal cyclers, and custom bioinformatics hardware interfaces. We are improving workflow efficiency, reducing turnaround times, and ensuring the accuracy and reliability of genetic testing pipelines used in oncology, rare disease diagnostics, and pharmacogenomics. We have scaled the lab’s capacity by 40% while maintaining rigorous quality standards and regulatory compliance with FDA and CAP guidelines.
Biomedical
Biotechnology
No badges yet
Professional Background
12 years
ISO 13485 medical device quality management and CLIA laboratory operations
Profile is not yet complete
Technical Interests & Expertise
Profile is not yet complete
In our lab, the sequencers are rarely the constraint. The slowest pieces are the handoffs between steps: tube thaw, decap, barcode scan, plate transport, tip changes, and the wait for a robot to be ready. When I value stream map from accessioning to data delivery, a surprising amount of time is idle or rework caused by tiny mismatches in labware, timing, or data sync.Over the past year we got more mileage from boring fixes than from any new instrument. We standardized plate height and seal type,...
Scaling our NGS prep lines taught me the slowest step isn’t a robot or thermocycler. It’s data handoff between instruments, LIMS, and people. Vendor apps export plate maps as quirky CSVs, barcode readers mix symbologies, and QC flags vary by platform. That meant avoidable queues, manual reconciliations, and the occasional misrouted sample.What helped was treating integrations like product, not glue. We defined interface contracts, shipped device simulators, and regression-tested against golden f...
In high throughput clinical genomics, we celebrate cycle times and samples per day. The metric I care about more is recoverability. When a liquid handler hiccups mid library prep or a thermocycler throws a temperature fault, can you contain the failure to a few wells and restart the run in minutes without compromising traceability? In a CLIA/CAP lab, that saves more patient reports than shaving 2 minutes from a protocol.What has worked for us: smaller independent batches with in line QC gates; i...
The biggest throughput gains in our NGS pipeline did not come from faster robots or shorter thermal profiles. They came from reducing variability. Once we treated the lab like a process control problem, scrap and rework dropped, and first pass yield went up enough to free real capacity.What helped most: daily gravimetric checks on liquid handlers, humidity control in pre-PCR, qualifying each tip lot, and building reagent-specific liquid classes with aspiration curves instead of one-size-fits-all...
Over the last year, scaling our genomics pipeline taught me that the real constraint isn’t pipetting speed. It’s data plumbing: LIMS-to-instrument handshakes, unambiguous sample tracking, and graceful exception handling.Our biggest gains came from standardizing metadata schemas, a sane barcoding strategy, and one source of truth for sample state transitions. Human-in-the-loop QC with a clear UI beat “full autonomy” by cutting rework. Turnaround improved more from eliminating mismatches than from...
In our NGS lab, the hardest part of scaling has not been robots; it is change control. A tiny edit to a liquid handler method or a PCR cycling profile can shift QC metrics and downstream calling. If that change is not traceable, root cause hunts get painful and expensive.What helped: treating wet lab methods like software. Every assay step has a version and a short changelog. We link each run to method version, instrument firmware, and reagent lot in the LIMS. We test changes in a sandbox lane w...
We all like to chase faster sequencers and shinier robots, but our throughput kept stalling. We borrowed OEE from manufacturing to see what was actually limiting our NGS pipeline.For labs, I map OEE this way: Availability equals instruments up and reagents and plates ready. Performance equals actual cycle time vs protocol ideal. Quality equals pass rate after QC. Our first pass was 54% even with a robot showing 100% utilization. The culprits were micro stops: decapping queues, plate seal cure ti...
Most genomics labs pour effort into automating the happy path. In practice, the bottlenecks are the 5% exceptions: misreads, partial aspirates, bent foils, odd sample volumes. I’ve seen robots idle while humans chase down a bad barcode or a plate that doesn’t quite meet spec.At Helix, our biggest throughput gains came from engineering the edges. We added simple checks and containment: inline imaging to catch seal issues, redundant ID verification before pooling, a quarantine lane for out-of-rang...
When we pushed our lab to handle 40% more samples, the surprising bottleneck wasn’t robot speed. It was safeguarding data integrity as complexity crept in. Minor pipetting bias after tip changes, lot-to-lot bead variability, and slow thermal cycler drift created rare but costly failure modes. We realized throughput only matters if every result remains defensible under audit.What helped most were small, boring controls. We added per-plate SPC on library QC metrics tied to reagent lots, per-well t...